CorMedix Inc. (NASDAQ:CRMD)
| Market Cap | $419.16M-46.3% |
| Revenue (ttm) | $412.49M+92.5% |
| Net Income | $63.89M-60.7% |
| EPS | $0.68-67.0% |
| Shares Out | 79.54M |
| PE Ratio | 6.59 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,608,270 |
| Open | $4.96 |
| Previous Close | $5.08 |
| Day's Range | $4.95 - $5.32 |
| 52-Week Range | $4.47 - $13.02 |
| Beta | 1.48 |
| Analysts | Buy |
| Price Target | $15.33(+190.89%) |
| Earnings Date | Mar 4, 2027 |
About CRMD
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
CorMedix Inc. Stock Analysis — InsiderScore
CorMedix Inc. scored higher than 94% of companies evaluated by InsiderBuying, and ranked 5th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at CorMedix Inc. bought $588.2K of stock across 4 purchases in the last 90 days, the largest of them $391.2K.
The average purchase added about 8% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating CRMD in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 4, 2027Earnings report
$CRMD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CRMD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CRMD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CRMD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CRMD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CRMD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CRMD
| AVUVAvantis U.S. Small Cap Value ETF | $14.89M |
| IWMiShares Russell 2000 ETF | $10.52M |
| VTIVanguard Morningstar Total Stock Market ETF | $10.00M |
| VIRSPacer BioThreat Strategy ETF | $4.93M |
| SZNEPacer CFRA-Stovall Equal Weight Seasonal Rotation ETF | $4.93M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $4.49M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CRMD’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 revenue beat despite net loss, but analyst price targets cut from $15 to $13-14 while maintaining Outperform ratings. Product growth catalysts noted but tempered by valuation adjustments.
Recent Insider Activity
Insider Score Trend Over Time
+12.6 since Nov 16Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 0.79% |
| FDM | First Trust Dow Jones Select MicroCap Index Fund | 0.50% |
| GERM | ETFMG Treatments, Testing and Advancements ETF | 0.49% |
| AESL | Harbor AlphaEdge Small Cap Value ETF | 0.25% |
| AESG | Harbor AlphaEdge Small Cap Growth ETF | 0.22% |
| AESB | Harbor AlphaEdge Small Cap Core ETF | 0.22% |
| AFSM | First Trust Active Factor Small Cap ETF | 0.21% |
| SQLV | Royce Quant Small-Cap Quality Value ETF | 0.19% |
| BFOR | ALPS ETF Trust - Barron's 400 ETF | 0.16% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.12% |
| ROSC | Hartford Multifactor Small Cap ETF | 0.11% |
| IWC | iShares Micro-Cap ETF | 0.10% |
Weight is the stock’s share of each fund’s holdings.
